Basic Stats
| LEI | 549300DR2I1DOPD2IX53 |
| CIK | 818033 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Heron Therapeutics, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commissio |
|
| August 15, 2025 |
Exhibit 3.1 CERTIFICATE OF DESIGNATIONS of SERIES B PREFERRED STOCK of Heron Therapeutics, inc. (Pursuant to Section 151 of the General Corporation Law of the State of Delaware) Heron Therapeutics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (hereinafter called the “Corporation”), hereby certifies that the following resolution was adopted b |
|
| August 15, 2025 |
Exhibit 99.1 Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value CARY, NC – August 15, 2025 – Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that its Board of Directors (the “Board”) has adopted a Section 382 rights plan (the “Rights Plan”) designed to protect the a |
|
| August 15, 2025 |
Exhibit 4.1 Heron Therapeutics, Inc. and Computershare Trust Company N.A. as Rights Agent Tax Benefit Preservation Plan Dated as of August 14, 2025 TAX BENEFIT PRESERVATION PLAN Tax Benefit Preservation Plan, dated as of August 14, 2025 (this “Plan”), between Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and Computershare Trust Company N.A., a limited liability trust company, a |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 (August 13, 2025) Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorpo |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 94-2875566 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 100 Regency F |
|
| August 12, 2025 |
Exhibit 10.5 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 8, 2025, by and among Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 (August 8, 2025) Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorpor |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2025 |
Exhibit 10.4 Execution Version NOTE PURCHASE AGREEMENT This Note Purchase Agreement (this “Agreement”) is entered into as of August 8, 2025 (the “Execution Date”) by and among Heron Therapeutics, Inc., a Delaware corporation (the “Company”), the purchasers from time to time party hereto (each, a “Purchaser”, and collectively, the “Purchasers”), and Rubric Capital Management LP, as agent for the Pu |
|
| August 12, 2025 |
SECOND AMENDMENT TO WORKING CAPITAL FACILITY AGREEMENT Exhibit 10.2 CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***]. Execution Version SECOND AMENDMENT TO WORKING CAPITAL FACILITY AGREEMENT THIS SECOND AMENDMENT TO WORKING CAPITAL FACILITY AGREEMENT (this “Amendment”) |
|
| August 12, 2025 |
Exhibit 10.3 Execution Version CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***]. Heron Therapeutics, Inc. Exchange Agreement August 8, 2025 Table of Contents Page Section 1. Definitions 3 Section 2. Rules of Constr |
|
| August 12, 2025 |
Exhibit 3.1 CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES AND PRIVILEGES OF SERIES A CONVERTIBLE PREFERRED STOCK OF HERON THERAPEUTICS, INC. PURSUANT TO SECTION 151 OF THE delaware GENERAL CORPORATION LAW THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Heron Therapeutics, Inc., a Delaware corporation (the “Corporation”), that the Board of Directors of the Corporation (the “Board of Directors |
|
| August 12, 2025 |
Exhibit 10.1 Execution Version COOPERATION AGREEMENT This Cooperation Agreement, dated as of August 8, 2025 (this “Agreement”), is made by and among Heron Therapeutics, Inc., a Delaware corporation (the “Company”) and Rubric Capital Management LP, a Delaware limited partnership (the “Investor”). The Company and the Investor are collectively herein referred to as the “Parties” and individually as a |
|
| August 8, 2025 |
Exhibit 10.1 CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***]. AMENDMENT NO.3 TO CO-PROMOTION AGREEMENT This Amendment No. 3 to the Co-Promotion Agreement (this “Amendment”) is made and entered into as of June 1, 2 |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEUTICS, |
|
| August 8, 2025 |
Exhibit 10.4 CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***]. AMENDMENT NO. 5 TO CO-PROMOTION AGREEMENT This Amendment No. 5 to the Co-Promotion Agreement (this “Amendment”) is made and entered into as of June 13, |
|
| August 8, 2025 |
Exhibit 99.2 Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile CARY, NC – August 8, 2025 – Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restructuring designed to enhance the Company’s financial flexibility, reduce to |
|
| August 8, 2025 |
Management Retention Agreement, dated April 28, 2025, by and between the Company and Mark Hensley Exhibit 10.3 HERON THERAPEUTICS, INC. MANAGEMENT RETENTION AGREEMENT This Management Retention Agreement (this “Agreement”) is dated as of April 28, 2025 (the “Effective Date”), by and between Mark Hensley (“Employee”) and Heron Therapeutics, Inc., a Delaware corporation (the “Company”). This Agreement is intended to provide Employee with certain benefits described herein upon the occurrence of sp |
|
| August 8, 2025 |
Exhibit 10.2 CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***]. AMENDMENT NO. 4 TO CO-PROMOTION AGREEMENT This Amendment No. 4 to the Co-Promotion Agreement (this “Amendment”) is made and entered into as of June 1, |
|
| August 8, 2025 |
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress Exhibit 99.1 Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress • Generated Q2 2025 Net Revenue of $37.2 million and year-to-date revenue of $76.1 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million • Delivered record year-to-date 2025 Adjusted EBITDA of $7.9 million, raised full-year 2025 Adjusted EBITDA Guidance from $4.0 million - |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| June 18, 2025 |
CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF HERON THERAPEUTICS, INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF HERON THERAPEUTICS, INC. Heron Therapeutics, Inc. (the “Corporation”), a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST: That, upon the Effective Time, Section A of Article IV of the Certificate of Incorporation of the Corporation, as |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| May 6, 2025 |
Form of Inducement Notice of Grant of Restricted Stock Units and Restricted Stock Unit Agreement* Exhibit 99.2 HERON THERAPEUTICS, INC. ID: 94-2875566 100 Regency Forest Drive Suite 300 Cary, North Carolina 27518 Notice of Grant of Award and Award Agreement Name: Address: Award Number: Plan: Amended and Restated 2007 Equity Incentive Plan Unless otherwise defined herein, the terms defined in the Amended and Restated 2007 Equity Incentive Plan (the “Plan”) shall have the same defined meanings i |
|
| May 6, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Heron Therapeutics, Inc. |
|
| May 6, 2025 |
Exhibit 99.1 Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations — Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 — CARY, May 6, 2025 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company entered |
|
| May 6, 2025 |
Exhibit 99.1 Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates • Generated Q1 2025 Net Revenue of $38.9 million • Delivered record Q1 2025 Adjusted EBITDA of $6.2 million • Reached settlement with Mylan Pharmaceuticals, Inc., regarding the parties’ CINVANTI® and APONVIE® patent litigations, including an agreed market entry date of June 1, 203 |
|
| May 6, 2025 |
Exhibit 99.3 Heron Therapeutics, Inc. ID: 94-2875566 100 Regency Forest Drive, Suite 300 Cary, NC 27518 Notice of Grant of Stock Options and Option Agreement [Name] Option Number: [To be inserted] [ADDRESS] Plan: [To be inserted] Effective [DATE], you have been granted a(n) Non-Qualified Stock Option to buy [NUMBER] shares of HERON THERAPEUTICS, INC. (the “Company” or “Heron”) stock at $ [PRICE] p |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEUTICS |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 6, 2025 |
As filed with the Securities and Exchange Commission on May 6, 2025 As filed with the Securities and Exchange Commission on May 6, 2025 Registration No. |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 6, 2025 |
Form of Inducement Notice of Grant of Stock Options and Option Agreement* Exhibit 99.1 HERON THERAPEUTICS, INC. ID: 94-2875566 100 Regency Forest Drive Suite 300 Cary, North Carolina 27518 Notice of Grant of Stock Options and Option Agreement Name: Address: Option Number: Plan: Amended and Restated 2007 Equity Incentive Plan Unless otherwise defined herein, the terms defined in the Amended and Restated 2007 Equity Incentive Plan (the “Plan”) shall have the same defined |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 30, 2025 |
Equity-Based Compensation (shares underlying awards) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| April 29, 2025 |
Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer Exhibit 99.1 Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer CARY, Apr. 28, 2025 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and op |
|
| February 27, 2025 |
Form of 2007 Equity Incentive Plan Restricted Stock Unit Agreement Exhibit 10.4 Heron Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan Notice of Restricted Stock Unit Grant Heron Therapeutics, Inc., a Delaware corporation (the “Company”) has awarded to you (“Awardee”) restricted stock units (“Restricted Stock Units”) covering the number of shares of Common Stock set forth below (the “Restricted Stock Unit Grant”) under its Amended and Restated 2 |
|
| February 27, 2025 |
Form of Indemnification Agreement Exhibit 10.5 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is entered into as of , 20 (the “Effective Date”) by and between Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and [] (the “Indemnitee”). RECITALS WHEREAS, the Board of Directors has determined that the inability to attract and retain qualified persons as directors and officers is detriment |
|
| February 27, 2025 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit is a part, Heron Therapeutics, Inc. (the “Company” or “we” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our |
|
| February 27, 2025 |
Exhibit 10.6 CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***]. AGREEMENT OF SUBLEASE THIS AGREEMENT OF SUBLEASE (this “Sublease”) is made as of September 23, 2024, by and between CROWN CASTLE USA INC., a Pennsylvan |
|
| February 27, 2025 |
Exhibit 19.1 Heron Therapeutics, Inc. Insider Trading Policy Heron Therapeutics, Inc. (the “Company”) has adopted this Insider Trading Policy (the “Policy”) to promote compliance with federal Securities laws by directors, officers, employees and contractors/consultants to the extent they are privy to Non-Public Material Information of the Company and its affiliates, as well as any immediate family |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEU |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commiss |
|
| February 27, 2025 |
Exhibit 99.1 Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates • Achieved Q4 2024 GAAP Net Income of $3.6 million • Generated full-year 2024 Net Revenue of $144.2 million, up 14% year-over-year • Delivered full-year 2024 adjusted EBITDA of $8.6 million • Generated ZYNRELEF® Q4 2024 Net Revenue of $8.5 million and launched the Z |
|
| February 27, 2025 |
Form of 2007 Equity Incentive Plan Stock Option Agreement Exhibit 10.3 Heron Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan Notice of Stock Option Grant Heron Therapeutics, Inc., a Delaware corporation (the “Company”) has awarded to you (“Awardee”) an option to purchase up to the number of shares of Common Stock set forth below (this “Option”) under its Amended and Restated 2007 Equity Incentive Plan (the “Plan”). Awardee Name: Grant |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commiss |
|
| February 20, 2025 |
Exhibit 10.1 FIRST AMENDMENT TO WORKING CAPITAL FACILITY AGREEMENT THIS FIRST AMENDMENT TO WORKING CAPITAL FACILITY AGREEMENT (this “Amendment”), dated as of February 13, 2025 (the “Amendment Effective Date”), is entered into by and among HERON THERAPEUTICS, INC., a Delaware corporation (“Company”), and each of its Qualified Subsidiaries from time to time party hereto (together with Company, indiv |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commiss |
|
| December 23, 2024 |
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina Exhibit 99.1 Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina SAN DIEGO, December 23, 2024 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, announced today the relocation of the Company’s headquarters from San Diego, California to Cary, North Carolina, effective January 1, 2025. A majo |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commissi |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commiss |
|
| November 12, 2024 |
Exhibit 10.1 CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***]. AMENDMENT NO.1 TO CO-PROMOTION AGREEMENT This Amendment No. 1 to the Co-Promotion Agreement (this “Amendment”) is made and entered into as of July 1, 2 |
|
| November 12, 2024 |
Exhibit 10.2 CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***]. AMENDMENT NO.2 TO CO-PROMOTION AGREEMENT This Amendment No. 2 to the Co-Promotion Agreement (this “Amendment”) is made and entered into as of September |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEU |
|
| November 12, 2024 |
SC 13G 1 p24-3088sc13g.htm HERON THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Heron Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Chec |
|
| November 12, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned ackn |
|
| November 12, 2024 |
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance Exhibit 99.1 Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance • Reported positive YTD 2024 Adjusted EBITDA of $1.4 million • Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million • ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle (“VAN”) approved in September and on track for Q4 2024 launch • |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commissi |
|
| November 4, 2024 |
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors Exhibit 99.1 Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors SAN DIEGO, November 4, 2024 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercia |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| August 6, 2024 |
Amended and Restated 1997 Employee Stock Purchase Plan* Exhibit 99.2 HERON THERAPEUTICS, INC. 1997 EMPLOYEE STOCK PURCHASE PLAN 1. PURPOSE. This Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan is designed to encourage and assist employees of Heron Therapeutics, Inc. and participating subsidiaries to acquire an equity interest in the Company through the purchase of shares of Company common stock. 2. DEFINITIONS. As used herein, the following |
|
| August 6, 2024 |
Form of Inducement Notice of Grant of Stock Options and Option Agreement* Exhibit 99.3 HERON THERAPEUTICS, INC. ID: 94-2875566 4242 Campus Point Court, Suite 200 San Diego, CA 92121 Notice of Grant of Stock Options and Option Agreement Name: Address: Option Number: Plan: Amended and Restated 2007 Equity Incentive Plan Unless otherwise defined herein, the terms defined in the Amended and Restated 2007 Equity Incentive Plan (the “Plan”) shall have the same defined meaning |
|
| August 6, 2024 |
Form of Inducement Notice of Grant of Restricted Stock Units and Restricted Stock Unit Agreement* Exhibit 99.4 HERON THERAPEUTICS, INC. ID: 94-2875566 4242 Campus Point Court, Suite 200 San Diego, CA 92121 Notice of Grant of Award and Award Agreement Name: Address: Award Number: Plan: Amended and Restated 2007 Equity Incentive Plan Unless otherwise defined herein, the terms defined in the Amended and Restated 2007 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this |
|
| August 6, 2024 |
As filed with the Securities and Exchange Commission on August 6, 2024 As filed with the Securities and Exchange Commission on August 6, 2024 Registration No. |
|
| August 6, 2024 |
Amended and Restated 2007 Equity Incentive Plan* Exhibit 99.1 HERON THERAPEUTICS, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purpose of this Plan is to encourage ownership in Heron Therapeutics, Inc., a Delaware corporation (the “Company”), by key personnel whose long-term employment or other service relationship with the Company is considered essential to the Company’s continued progress and, thereby, enco |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEUTICS, |
|
| August 6, 2024 |
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance • Second quarter Net Product Sales of $36.0 million, which increased from $31.8 million for the same period in 2023 • ZYNRELEF® Vial Access Needle (“VAN”) PDUFA goal date set for September 23, 2024 • ZYNRELEF included in the proposed 2025 Non-Opioid Policy for Pain Relief (“NOPAIN Act”) S |
|
| August 6, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Heron Therapeutics, Inc. |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2024 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission F |
|
| July 2, 2024 |
Exhibit 99.1 Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle (“VAN”) -The U.S. Food and Drug Administration (“FDA”) assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of September 23, 2024 SAN DIEGO, July 2, 2024 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biot |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| June 18, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF HERON THERAPEUTICS, INC. Heron Therapeutics, Inc. (the “Corporation”), a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST: That, upon the Effective Time, Section A of Article IV of the Certificate of Incorporation of the Corporation, as |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Heron Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) Rubric Capita |
|
| May 29, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission F |
|
| May 29, 2024 |
Exhibit 99.1 Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle (“VAN”) SAN DIEGO, May 29, 2024 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the Prior Approval Supplement (“PAS”) submission to the U.S. Food and Drug Administration (“FDA”) for ZY |
|
| May 7, 2024 |
Exhibit 10.1 CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***]. CO-PROMOTION AGREEMENT THIS CO-PROMOTION AGREEMENT (the “Agreement”) is dated this 5th day of January, 2024, but effective as of January 1, 2024 (the “ |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEUTICS |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 7, 2024 |
318509926.1 Exhibit 99.1 Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates • Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02), which decreased from $(0.27) for the same period in 2023. • Launched partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF® prom |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEU |
|
| March 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| March 12, 2024 |
Exhibit 97.1 Heron Therapeutics, Inc. Compensation Recovery Policy Overview It is the policy of Heron Therapeutics, Inc. (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements due to the Company’s material non-compliance with any financial reporting requirement under the federal securities laws (including any such corre |
|
| March 12, 2024 |
EXHIBIT 99.1 Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates • 2023 oncology care franchise revenue was $107.9 million, exceeding full-year 2023 guidance • ZYNRELEF® achieved quarterly record of $5.6 million in Q4 Net Product Sales • Ended 2023 with cash and cash equivalents of $80.4 million • Announced partnership with Cross |
|
| February 14, 2024 |
HRTX / Heron Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
HRTX / Heron Therapeutics, Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-hrtx123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* HERON THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 14, 2024 |
HRTX / Heron Therapeutics, Inc. / GREAT POINT PARTNERS LLC Passive Investment SC 13G/A 1 greatpoint-hrtx123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* HERON THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 13, 2024 |
HRTX / Heron Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Heron Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 427746102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| February 6, 2024 |
HRTX / Heron Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment hero23a13.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 427746102 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13)* HERON THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) December 31, 2023 (D |
|
| January 24, 2024 |
Exhibit 99.1 Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures – Expanded indication for ZYNRELEF now covers approximately 13 million procedures annually – SAN DIEGO, January 23, 2024 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Fo |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2024 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commissi |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commissio |
|
| January 11, 2024 |
EX-99.1 Exhibit 99.1 Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain SAN DIEGO, January 7, 2024 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it has entered into a five-year dist |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commiss |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commiss |
|
| December 7, 2023 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* HERON THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) November 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| December 6, 2023 |
HRTX / Heron Therapeutics Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us4277461020120623.txt us4277461020120623.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) HERON THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 427746102 - (CUSIP Number) November 30, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commiss |
|
| November 14, 2023 |
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance EXHIBIT 99.1 Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance • Heron is increasing full-year 2023 Net Product Sales guidance for the oncology care franchise to a range of $104 million to $106 million from a prior range of $99 million to $103 million • We anticipate full-year 2023 Net Product Sales to be in the range of $123 million to $125 million a |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEU |
|
| September 6, 2023 |
Prospectus 21,897,808 Shares of Common Stock 424B3 Table of Contents As Filed Pursuant to Rule 424(b)(3) Registration No. 333-274167. Prospectus 21,897,808 Shares of Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of 21,897,808 shares of common stock, par value $0.01 per share (the “Common Stock”), of Heron Therapeutics, Inc. (“Heron |
|
| August 30, 2023 |
Heron Therapeutics, Inc. 4242 Campus Point Court, Suite 200 | San Diego, CA 92121 Heron Therapeutics, Inc. 4242 Campus Point Court, Suite 200 | San Diego, CA 92121 August 29, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Re: Heron Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-274167) To Whom it May Concern: Pursuant to Rule 461 under the Securities Act of 19 |
|
| August 23, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Heron Therapeutics, Inc. |
|
| August 23, 2023 |
As filed with the Securities and Exchange Commission on August 23, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 23, 2023 Registration No. |
|
| August 14, 2023 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of April 3, 2023 (the “Effective Date”), by and between HERON THERAPEUTICS, INC. (the “Company”), and CRAIG COLLARD (the “Executive”). The Company and the Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”. AGREEME |
|
| August 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commissio |
|
| August 14, 2023 |
Exhibit 10.10 Execution Version Working capital FACILITY AGREEMENT THIS WORKING CAPITAL FACILITY AGREEMENT is made and dated as of August 9, 2023 and is entered into by and among HERON THERAPEUTICS, INC., a Delaware corporation (“Company”), and each of its Qualified Subsidiaries from time to time party hereto (together with Company, individually or collectively, as the context may require, “Borrow |
|
| August 14, 2023 |
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates EXHIBIT 99.1 Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates • Company is well capitalized after signing $50 million working capital credit facility and recent $30 million equity raise • Favorable outcome at Markman hearing in pending CINVANTI® ANDA patent litigation • New management team in place • Reiterating full-year net product sales guidance |
|
| August 14, 2023 |
Exhibit 10.3 HERON THERAPEUTICS, INC. MANAGEMENT RETENTION AGREEMENT This Management Retention Agreement (this “Agreement”) is dated as of June 6, 2023 (the “Effective Date”), by and between William Forbes (“Employee”) and Heron Therapeutics, Inc., a Delaware corporation (the “Company”). This Agreement is intended to provide Employee with certain benefits described herein upon the occurrence of sp |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEUTICS, |
|
| August 14, 2023 |
Exhibit 10.4 HERON THERAPEUTICS, INC. MANAGEMENT RETENTION AGREEMENT This Management Retention Agreement (this “Agreement”) is dated as of June 16, 2023 (the “Effective Date”), by and between Ira Duarte (“Employee”) and Heron Therapeutics, Inc., a Delaware corporation (the “Company”). This Agreement is intended to provide Employee with certain benefits described herein upon the occurrence of speci |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Heron Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) Rubric Capita |
|
| July 24, 2023 |
Heron Therapeutics Announces $30 Million Private Placement Financing EX-99.1 Exhibit 99.1 Heron Therapeutics Announces $30 Million Private Placement Financing SAN DIEGO, July 24, 2023 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, announced today that it has entered into a securities purcha |
|
| July 24, 2023 |
EX-10.2 Exhibit 10.2 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment to the Executive Employment Agreement (this “Amendment”) by and between HERON THERAPEUTICS, INC. (the “Company”), and DAVID SZEKERES (the “Executive”) is effective as of May 05, 2023. WHEREAS, the Executive and the Company are parties to the Executive Employment Agreement dated as of March 17, 2016 (the “Original Agree |
|
| July 24, 2023 |
EX-99.2 Exhibit 99.2 Heron Therapeutics Announces Cost Reduction Plan and Restructuring - Expected overall cash savings of $75 million through 2025 - New executive management team in place SAN DIEGO, July 24, 2023 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic |
|
| July 24, 2023 |
EX-10.1 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 21, 2023, by and among Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”). RE |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| June 30, 2023 |
EX-99.2 Exhibit 99.2 HERON THERAPEUTICS, INC. 1997 EMPLOYEE STOCK PURCHASE PLAN (as amended through June 8, 2023) 1. PURPOSE. This Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan is designed to encourage and assist employees of Heron Therapeutics, Inc. and participating subsidiaries to acquire an equity interest in the Company through the purchase of shares of Company common stock. 2. D |
|
| June 30, 2023 |
Form of Inducement Notice of Grant of Restricted Stock Units and Restricted Stock Unit Agreement*. EX-99.4 Exhibit 99.4 HERON THERAPEUTICS, INC. ID: 94-2875566 4242 Campus Point Court, Suite 200 San Diego, CA 92121 Notice of Grant of Award and Award Agreement Name: Award Number: Address: Plan: Amended and Restated 2007 Equity Incentive Plan Unless otherwise defined herein, the terms defined in the Amended and Restated 2007 Equity Incentive Plan (the “Plan”) shall have the same defined meanings |
|
| June 30, 2023 |
EX-99.1 Exhibit 99.1 HERON THERAPEUTICS, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purpose of this Plan is to encourage ownership in Heron Therapeutics, Inc., a Delaware corporation (the “Company”), by key personnel whose long-term employment or other service relationship with the Company is considered essential to the Company’s continued progress and, there |
|
| June 30, 2023 |
Power of Attorney (included on the signature page)*. S-8 As filed with the Securities and Exchange Commission on June 30, 2023 Registration No. |
|
| June 30, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Heron Therapeutics, Inc. |
|
| June 30, 2023 |
EX-99.3 Exhibit 99.3 HERON THERAPEUTICS, INC. ID: 94-2875566 4242 Campus Point Court, Suite 200 San Diego, CA 92121 Notice of Grant of Stock Options and Option Agreement Name: Option Number: Address: Plan: Amended and Restated 2007 Equity Incentive Plan Unless otherwise defined herein, the terms defined in the Amended and Restated 2007 Equity Incentive Plan (the “Plan”) shall have the same defined |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| June 23, 2023 |
Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer Exhibit 99.1 Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer SAN DIEGO, June 23, 2023 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Ira Dua |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission F |
|
| June 12, 2023 |
Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer Exhibit 99.1 Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer SAN DIEGO, June 12, 2023 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the appoin |
|
| June 12, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF HERON THERAPEUTICS, INC. Heron Therapeutics, Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Corporation” and the “DGCL”, respectively), does hereby certify: FIRST: That, upon the Effective Time, Section A of Article IV of the Certificate of Incorporation of |
|
| May 11, 2023 |
EXHIBIT 99.1 Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates • Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million, Compared to First Quarter Net Product Sales in 2022 • Appointment of Craig Collard as Chief Executive Officer (CEO) and Jason Grillot as Vice President (VP), Sales and Marketing, of the |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission F |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEUTICS |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 20, 2023 |
Heron Therapeutics Announces Commercial Leadership Changes Exhibit 99.1 Heron Therapeutics Announces Commercial Leadership Changes SAN DIEGO, April 20, 2023 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron”), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced changes to its commercial leadership team, includin |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 (April 18, 2023) Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorpora |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 13, 2023 |
HRTX / Heron Therapeutics Inc / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 3, 2023 |
Exhibit 99.1 Heron Therapeutics Announces New CEO and Board Chairman Craig Collard Appointed CEO Adam Morgan Named Chairman of the Board SAN DIEGO, April 3, 2023 /PRNewswire/ - Heron Therapeutics, Inc. (NASDAQ: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEU |
|
| March 23, 2023 |
EXHIBIT 99.1 Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates - Annual Net Product Sales Across the Company Grew 25% to $107.7 million in 2022, Compared to Annual Net Product Sales in 2021 - - APONVIE™Commercially Launched on March 6, 2023 - - ZYNRELEF® Net Product Sales for Fourth Quarter of 2022 Increas |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| March 13, 2023 |
Exhibit 99.1 Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIETM, Effective April 1, 2023 SAN DIEGO, March 13, 2023 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most imp |
|
| March 6, 2023 |
EX-99 2 hrtx-ex991.htm EX-99.1 Exhibit 99.1 Heron Therapeutics Announces U.S. Commercial Launch of APONVIETM for the Management of Postoperative Nausea and Vomiting in Adults - APONVIE, the first and only intravenous (IV) formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for Postoperative Nausea and Vomiting (PONV) - - APONVIE is delivered via a single IV push and offer |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Heron Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) Velan Capital |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (Date of earliest event reported): February 22, 2023 (February 21, 2023) HERON THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33221 94-2875566 (State or Other Jurisdiction of Inc |
|
| February 22, 2023 |
EX-10.1 Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement, dated as of February 21, 2023 (this “Agreement”), is made by and among Heron Therapeutics, Inc., a Delaware corporation (the “Company”), Rubric Capital Management LP, a Delaware limited partnership (and collectively with the other persons and entities listed on Schedule A hereto, “Rubric”), and Velan Capital Investment Manageme |
|
| February 22, 2023 |
Exhibit 99.1 Execution Version COOPERATION AGREEMENT This Cooperation Agreement, dated as of February 21, 2023 (this “Agreement”), is made by and among Heron Therapeutics, Inc., a Delaware corporation (the “Company”), Rubric Capital Management LP, a Delaware limited partnership (and collectively with the other persons and entities listed on Schedule A hereto, “Rubric”), and Velan Capital Investmen |
|
| February 22, 2023 |
Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, par value $0.01 per share, of Heron Therapeutics, Inc., a Delaware corporation. This |
|
| February 22, 2023 |
EX-99.1 3 d457589dex991.htm EX-99.1 Exhibit 99.1 Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital Appoints Three New Independent Directors SAN DIEGO—February 22, 2023—Heron Therapeutics, Inc. (NASDAQ: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing thera |
|
| February 15, 2023 |
HRTX / Heron Therapeutics Inc / ArrowMark Colorado Holdings LLC Passive Investment SC 13G/A 1 arrowmark-hrtx123122a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Heron Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 14, 2023 |
HRTX / Heron Therapeutics Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 3 Passive Investment SC 13G/A 1 hrtx28231sc13ga3.htm AMENDMENT NO. 3 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Heron Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check th |
|
| February 13, 2023 |
HRTX / Heron Therapeutics Inc / UBS OCONNOR LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Heron Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 9, 2023 |
HRTX / Heron Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01072-herontherapeuticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Heron Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 427746102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to |
|
| February 6, 2023 |
Exhibit 99.1 GROUP AGREEMENT THIS AGREEMENT, dated as of January 30, 2023 (the “Effective Date”), is by and between (i) Velan Capital Master Fund LP, Velan Capital Holdings LLC, Velan Capital Investment Management LP, Velan Capital Management LLC, Adam Morgan and Balaji Venkataraman (collectively, “Velan”) and (ii) Rubric Capital Management LP and in his capacity as managing member of Rubric Capit |
|
| February 6, 2023 |
HRTX / Heron Therapeutics Inc / Rubric Capital Management LP - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Heron Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) Velan Capital |
|
| January 31, 2023 |
HRTX / Heron Therapeutics Inc / FRANKLIN RESOURCES INC Passive Investment SC 13G/A 1 hero22a121.htm CUSIP NO. 427746102 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12)* HERON THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Fili |
|
| January 23, 2023 |
SC 13G/A 1 HERONTHERAPEUTICSINC.htm FILING HERON THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* HERON THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) December 30, 2022 (Date of Event Which Requires |
|
| January 9, 2023 |
Exhibit 99.1 Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises - Preliminary Annual Net Product Sales Across the Company Grew 24% to $106.7 Million in 2022, Compared to Annual Net Product Sales in 2021 - - Preliminary Fourth-Quarter 2022 Net Product Sales for ZYNRELEF® Increased 40% to Approximately $3.8 Million - - Preliminary Full-Year 2022 Net Product Sales for O |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commissio |
|
| December 29, 2022 |
Exhibit 99.1 Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF - Supplemental New Drug Application Submitted Requesting Expansion of Indication to Broadly Cover Soft Tissue and Orthopedic Surgical Procedures - - Omnibus Spend |
|
| December 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2022 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commiss |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEU |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commissi |
|
| November 8, 2022 |
EXHIBIT 99.1 Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates - APONVIE™ approval by FDA, U.S. launch planned for Q1 2023 – - ZYNRELEF® unit demand grew 18% over prior quarter in Q3 2022 – - Oncology Care Franchise net product sales grew 13% over prior year in Q3 2022 – SAN DIEGO, Nov. 8, 2022 /PRNewswire/ |
|
| October 20, 2022 |
24,677,419 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267781 Prospectus 24,677,419 Shares of Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of 24,677,419 shares of common stock, par value $0.01 per share (the “Common Stock”), of Heron Therapeutics, Inc. (“Heron,” “ |
|
| October 13, 2022 |
CORRESP 1 filename1.htm Heron Therapeutics, Inc. 4242 Campus Point Court, Suite 200 San Diego, California 92121 (858) 251-4400 October 13, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Jason Drory Re: Heron Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-267781) To Who |
|
| October 7, 2022 |
Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) HERON THERAPEUTICS, INC. |
|
| October 7, 2022 |
As filed with the Securities and Exchange Commission on October 7, 2022 Table of Contents As filed with the Securities and Exchange Commission on October 7, 2022 Registration No. |
|
| September 19, 2022 |
APONVIE? (HTX-019) FDA Approval September 19, 2022 Exhibit 99.2 This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management?s expectations and assumptions as of the date of this presentation, and involve substantial risks and uncertainties that could cause ou |
|
| September 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 (September 16, 2022) Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of i |
|
| September 19, 2022 |
Exhibit 99.1 Heron Therapeutics Announces U.S. FDA Approval of APONVIETM (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV) - APONVIE is the first and only intravenous (IV) formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for PONV - - Delivered via a single 30-second IV injection, APONVIE has demonstrated rapid achievement of therapeutic drug leve |
|
| September 9, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) HERON THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par va |
|
| September 9, 2022 |
As filed with the Securities and Exchange Commission on September 9, 2022 As filed with the Securities and Exchange Commission on September 9, 2022 Registration No. |
|
| September 9, 2022 |
1997 Employee Stock Purchase Plan (as amended through May 24, 2022)*. EXHIBIT 99.2 HERON THERAPEUTICS, INC. 1997 EMPLOYEE STOCK PURCHASE PLAN (as amended through May 24, 2022) 1. PURPOSE. This Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan is designed to encourage and assist employees of Heron Therapeutics, Inc. and participating subsidiaries to acquire an equity interest in the Company through the purchase of shares of Company common stock. 2. DEFINITIO |
|
| September 9, 2022 |
Amended and Restated 2007 Equity Incentive Plan*. EXHIBIT 99.1 HERON THERAPEUTICS, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purpose of this Plan is to encourage ownership in Heron Therapeutics, Inc., a Delaware corporation (the ?Company?), by key personnel whose long-term employment or other service relationship with the Company is considered essential to the Company?s continued progress and, thereby, enco |
|
| August 19, 2022 |
HRTX / Heron Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Heron Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33221 94-2875566 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 10, 2022 |
Exhibit 10.1 Execution Copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of August 8, 2022, by and among Heron Therapeutics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a ?Purchaser? and collectively, the ?Purchasers?). RECITALS A. |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEUTICS, |
|
| August 9, 2022 |
EXHIBIT 10.3 FIRST AMENDMENT TO MANAGEMENT RETENTION AGREEMENT THIS FIRST AMENDMENT TO MANAGEMENT RETENTION AGREEMENT (this ?Amendment?) is made and entered into as of August 8, 2022 (the ?Amendment Effective Date?), by and between Heron Therapeutics, Inc., with its principal address located at 4242 Campus Point Court, Suite 200, San Diego, California 92121 (the ?Company?) and Lisa Peraza (the ?Em |
|
| August 9, 2022 |
EXHIBIT 10.2 FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this ?Amendment?) is made and entered into as of August 8, 2022 (the ?Amendment Effective Date?), by and between Heron Therapeutics, Inc., with its principal address located at 4242 Campus Point Court, Suite 200, San Diego, California 92121 (the ?Company?) and John Poyhonen (the ? |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| August 9, 2022 |
EXHIBIT 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into effective as of March 17, 2016 (the ?Effective Date?), by and between HERON THERAPEUTICS, INC. (the ?Company?), and DAVID SZEKERES (the ?Executive?). The Company and the Executive are hereinafter collectively referred to as the ?Parties?, and individually referred to as a ?Party?. AGREE |
|
| August 9, 2022 |
EXHIBIT 99.1 Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates - ZYNRELEF? launch trend continues at a strong pace with sequential quarterly product sales increase of 140% and unit demand increase of 47% - - Oncology Care Franchise net product sales grew 12% over the prior quarter to $25.1 million in Q2 2022, lea |
|
| June 30, 2022 |
Exhibit 99.1 Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability - Changes result in annualized cost savings of $43M, extending the cash runway; Company is continuing to reduce external spend - - Reduces organization headcount by 34% - - Priorities remain on commercial growth for both the Acute Care and Oncology Car |
|
| June 30, 2022 |
Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| June 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| June 14, 2022 |
Exhibit 99.1 Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty SAN DIEGO, June 14, 2022 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by d |
|
| May 25, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission F |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEUTICS |
|
| May 9, 2022 |
EXHIBIT 99.1 Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates - ZYNRELEF? unit demand increased 68% in the first quarter compared to the prior quarter - - Centers for Medicare and Medicaid Services approved a 3-year transitional pass-through status for ZYNRELEF beginning April 1, 2022 to support separate reimbursement |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 14, 2022 |
PRE 14A 1 hrtx-pre14a20220616.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| March 25, 2022 |
ZYNRELEF?s Significant Economic Benefit With Pass-Through Status March 25, 2022 Exhibit 99. |
|
| March 25, 2022 |
Exhibit 99.1 Heron Therapeutics Secures Pass-through Payment Status for ZYNRELEF? from Centers for Medicare & Medicaid Services, Expanding Separate Reimbursement into the Hospital Outpatient Setting of Care - ZYNRELEF is the only local anesthetic with separate reimbursement in both the Hospital Outpatient and Ambulatory Surgical Center settings of care - SAN DIEGO, March 25, 2022 /PRNewswire/ - He |
|
| March 25, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2022 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| March 17, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| March 17, 2022 |
Exhibit 99.1 Heron Therapeutics Announces Approval of ZYNRELEF? by Health Canada for the Management of Postoperative Pain - ZYNRELEF is the first and only extended-release local anesthetic approved by Health Canada - SAN DIEGO, Mar. 17, 2022 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEU |
|
| February 28, 2022 |
EXHIBIT 99.1 Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates - ZYNRELEF? has received 260 formulary approvals since initial launch in July 2021, with over a 90% hospital approval rate and over 60% of approvals have been for unrestricted usage - - Over 300 unique accounts purchased ZYNRELEF with 70% of th |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commiss |
|
| February 14, 2022 |
HRTX / Heron Therapeutics Inc / UBS OCONNOR LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Heron Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2022 |
HRTX / Heron Therapeutics Inc / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
HRTX / Heron Therapeutics Inc / ArrowMark Colorado Holdings LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
HRTX / Heron Therapeutics Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 2 Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2022 |
HRTX / Heron Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Heron Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 427746102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* HERON THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 427746102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 3, 2022 |
HRTX / Heron Therapeutics Inc / FRANKLIN RESOURCES INC Passive Investment hero21a11.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 427746102 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* HERON THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) December 31, 2021 (D |
|
| January 24, 2022 |
SC 13G 1 HERONTHERAPEUTICSINC.htm FILING HERON THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HERON THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 427746102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Fil |
|
| December 9, 2021 |
Exhibit 99.1 Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF? - Approval provides a significantly broader indication for ZYNRELEF, now covering approximately 7 million procedures a year - - Conference call and webcast today, December 9, 2021 at 8:30 a.m. ET - SAN DIEGO, Dec. 9, 2021 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-st |
|
| December 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commissi |
|
| November 18, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2021 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commiss |
|
| November 18, 2021 |
Exhibit 99.1 Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA SAN DIEGO, Nov. 18, 2021 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today |
|
| November 3, 2021 |
EXHIBIT 99.1 Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates - ZYNRELEF? net product sales of $2.1 million in its first quarter of launch with 160 unique accounts already purchasing ZYNRELEF and 50% of those accounts reordering - - ZYNRELEF has received 126 formulary approvals, representing over a 91% hos |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commissi |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEU |
|
| November 3, 2021 |
EXHIBIT 10.1 FOURTH AMENDMENT TO LEASE THIS FOURTH AMENDMENT TO LEASE (this ?Fourth Amendment?) is made as of October 13, 2021, by and between ARE-SD REGION NO. 61, LLC, a Delaware limited liability company (?Landlord?), and HERON THERAPEUTICS, INC., a Delaware corporation (?Tenant?). RECITALS A. Landlord and Tenant are now parties to that certain Lease dated as of October 18, 2016, as amended by |
|
| October 4, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2021 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commissio |
|
| October 4, 2021 |
Exhibit 99.1 Heron Therapeutics Announces Filing of a Supplemental New Drug Application for Significant Expansion of ZYNRELEF? Indication Statement Based on Successful Outcome of FDA Type C Meeting - FDA agreed to the immediate filing of supplemental NDA to significantly expand the ZYNRELEF indication statement based on previously submitted data with no new clinical studies - - FDA also agreed on |
|
| September 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2021 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commis |
|
| September 14, 2021 |
Amended and Restated 2007 Equity Incentive Plan*. Exhibit 99.1 HERON THERAPEUTICS, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purpose of this Plan is to encourage ownership in Heron Therapeutics, Inc., a Delaware corporation (the ?Company?), by key personnel whose long-term employment or other service relationship with the Company is considered essential to the Company?s continued progress and, thereby, enco |
|
| September 14, 2021 |
As filed with the Securities and Exchange Commission on September 14, 2021 As filed with the Securities and Exchange Commission on September 14, 2021 Registration No. |
|
| September 14, 2021 |
1997 Employee Stock Purchase Plan (as amended through June 17, 2021)*. Exhibit 99.2 HERON THERAPEUTICS, INC. 1997 EMPLOYEE STOCK PURCHASE PLAN (as amended through June 17, 2021) 1. PURPOSE. This Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan is designed to encourage and assist employees of Heron Therapeutics, Inc. and participating subsidiaries to acquire an equity interest in the Company through the purchase of shares of Company common stock. 2. DEFINITI |
|
| August 10, 2021 |
August 10, 2021 VIA EDGAR Mary Mast Angela Connell United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D. |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEUTICS, |
|
| August 9, 2021 |
EXHIBIT 99.1 Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate Updates - ZYNRELEF? Commercially Launched on July 1, 2021 with 61 Unique Accounts Already Purchasing the Product and Multiple Commercial and Medicaid Payers Covering 86 Million Lives Agreeing to Reimburse ZYNRELEF - - The Oncology Care Franchise Continued to |
|
| August 2, 2021 |
Letter from OUM, dated August 2, 2021 EXHIBIT 16.1 August 2, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549-7561 Ladies and Gentlemen: We have read Heron Therapeutics, Inc.?s statements included under Item 4.01 of its Form 8?K dated August 2, 2021, and are in agreement with the statements contained therein concerning our firm in response to Item 304(a) of Regulation S-K. Very truly yours, /s/ OUM & Co. |
|
| August 2, 2021 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| June 17, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission |
|
| May 28, 2021 |
As filed with the Securities and Exchange Commission on May 28, 2021 Table of Contents As filed with the Securities and Exchange Commission on May 28, 2021 Registration No. |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 (May 24, 2021) Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation |
|
| May 25, 2021 |
Exhibit 10.1 EXECUTION VERSION NOTE PURCHASE AGREEMENT This Note Purchase Agreement (this ?Agreement?) is entered into as of May 24, 2021 (the ?Execution Date?) by and among Heron Therapeutics Inc., a Delaware corporation (the ?Company?), the purchasers from time to time party hereto (each, a ?Purchaser?, and collectively, the ?Purchasers?), and Baker Bros. Advisors LP, as agent for the Purchasers |
|
| May 13, 2021 |
Exhibit 99.1 Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF? (HTX-011) for the Management of Postoperative Pain for up to 72 Hours - ZYNRELEF is the first and only FDA-approved extended-release dual-acting local anesthetic, clinically proven to manage pain and to eliminate the need for opioids for up to 72 hours following surgery better than bupivacaine solution, the current standard-o |
|
| May 13, 2021 |
Approval May 13, 2021 Exhibit 99.2 This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management?s expectations and assumptions as of the date of this presentation, and involve substantial risks and uncertainties that could cause our clinical development progra |
|
| May 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission F |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEUTICS |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission F |
|
| May 10, 2021 |
EXHIBIT 99.1 Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Recent Corporate Updates - Labelling Discussions with the FDA are Underway for HTX-011; Prescription Drug User Fee Act (PDUFA) Goal Date is May 12, 2021 - SAN DIEGO, May 10, 2021 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| February 24, 2021 |
EXHIBIT 99.1 Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates SAN DIEGO, Feb. 24, 2021 /PRNewswire/ - Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important un |
|
| February 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEU |
